Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Investigational New Drugs|June 1, 1988
In vivo and in vitro investigations on biological effects of aromatic bis-(2-chloroethyl)amino-bisphosphonic acids, new agents proposed for chemotherapy of bone tumors: cytostatic activity in rat osteosarcoma; toxicity and genotoxicity in liver and bone marrow; mutagenicity in S. typhimuriumB L Pool, M Berger, J R Schlehofer, et al.
International Journal of Radiation Applications and Instrumentation. Part A, Applied Radiation and Isotopes|January 1, 1986
Iodine-131-labeled diphosphonates for the palliative treatment of bone metastases--III. Considerations of interaction, binding and absorbed doseM Eisenhut, P Fritz, B Kimmig, et al.
Oncology|January 1, 1988
Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256B Krempien, F Wingen, T Eichmann, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1990
Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?T Klenner, F Wingen, B K Keppler, et al.
Investigational New Drugs|September 1, 1988
Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agentsF Wingen, B L Pool, P Klein, et al.
Bone Marrow Transplantation|May 1, 1993
Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMTH Link, H F Vöhringer, F Wingen, et al.
Clinical & Experimental Metastasis|July 1, 1990
Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the ratT Klenner, F Wingen, B Keppler, et al.
Arzneimittel-Forschung|June 1, 1989
Assessment of the preclinical activity of budotitane in three different transplantable tumor systems, its lack of mutagenicity, and first results of clinical phase I studiesB K Keppler, M E Heim, H Flechtner, et al.
Medizinische Klinik (Munich, Germany : 1983)|October 1, 1992
[Risk factors and prevention of pneumocystis carinii pneumonia after bone marrow transplantation]H Link, H F Vöhringer, F Wingen, et al.
Archiv Fur Geschwulstforschung|January 1, 1989
Evaluation of spin labeled TEPA and CCNU analogs against osteosarcoma and MNU-induced mammary carcinoma of the SD-ratT Klenner, M R Berger, G Sosnovsky, et al.
Pageof 3